Ali Ahmed M, Bachman Katelynn C, Worrell Stephanie G, Gray Kelsey E, Perry Yaron, Linden Philip A, Towe Christopher W
Division of Thoracic and Esophageal Surgery, Department of Surgery, University Hospitals Cleveland Medical Center and Case Western Reserve School of Medicine, Cleveland, OH, USA, 44106-5011, 11100 Euclid Avenue.
Surg Endosc. 2021 Nov;35(11):6329-6334. doi: 10.1007/s00464-020-08120-3. Epub 2020 Nov 10.
Robotic minimally invasive esophagectomy (RMIE) and "traditional" minimally invasive esophagectomy techniques (tMIE) have reported superior outcomes relative to open techniques. Differences in the outcomes of these two approaches have not been examined. We hypothesized that short-term outcomes of RMIE would be superior to tMIE.
The National Cancer Database was used to analyze outcomes of patients undergoing RMIE and tMIE from 2010 to 2016. Patients with clinical metastatic disease were excluded. Trends in the number of procedures performed with each approach were described using linear regression testing. Primary outcome of interest was 90-day mortality rate. Secondary outcomes of interest were positive surgical margin rate, number of lymph nodes (LN) removed, adequate lymphadenectomy (> 15 LNs), length of hospitalization (LOS), readmission rate, and conversion to open rate. Outcomes of RMIE and tMIE were compared using Wilcoxon rank sum test and chi square test as appropriate. Multivariable regression was also performed to reduce the impact of differences in the cohorts of patients receiving RMIE and tMIE.
6661 minimally invasive esophagectomies were performed from 2010 to 2016 (1543/6661 (23.2%) RMIE and 5118/6661 (76.8%) tMIE). Over the study period, the proportion of RMIE increased from 10.4% (64/618) in 2010 to 27.2% (331/1216) in 2016 (p < 0.001) (Fig. 1). The primary outcome of 90-day mortality was similar between RMIE and tMIE (92/1170 (7.4%) vs 305/4148 (7.9%), p = 0.558) (Table 2). RMIE and tMIE also had similar readmission rate (6.3 vs 7%, p = 0.380). There was no difference between the cohorts based on sex, age, race, insurance, and tumor size. The cohorts of patients receiving RMIE and tMIE differed in that RMIE patients had lower rates of elevated Charlson scores, were more likely to be treated at an academic institution, had a higher rate of advanced clinical T-stage and clinical nodal involvement, and had received neoadjuvant therapy. In a univariate analysis, RMIE had a lower rate of positive margin (3.9 vs 6.1%, p = 0.001), more mean lymph nodes evaluated (16.6 ± 9.74 vs 16.1 ± 10.08 p = 0.018), lower conversion to open rate (5.4 vs 11.4%, p < 0.001), and a shorter mean length of stay (12.1 ± 10.39 vs 12.8 ± 11.18 days, p < 0.001). In multivariable analysis, RMIE was associated with lower risk of conversion to open (OR 0.51, 95% CI: 0.37-0.70, p < 0.001) and lower rate of positive margin (OR 0.62, 95% CI: 0.41-0.93, p = 0.021).). Additionally, in a multivariable logistic regression, RMIE demonstrated superior adequate lymphadenectomy (> 15 LNs) (OR 1.18, 95% CI 1.02-1.37, p < 0.032).
In the National Cancer Database, robotic esophagectomy is associated with superior rate of conversion to open and positive surgical margin status. We speculate enhanced dexterity and visualization of RMIE facilitates intraoperative performance leading to improvement in these outcomes.
与开放手术相比,机器人微创食管切除术(RMIE)和“传统”微创食管切除术技术(tMIE)已报告具有更好的治疗效果。这两种手术方式在治疗效果上的差异尚未得到研究。我们假设RMIE的短期治疗效果优于tMIE。
利用国家癌症数据库分析2010年至2016年接受RMIE和tMIE治疗的患者的治疗效果。排除临床转移性疾病患者。使用线性回归测试描述每种手术方式的手术例数趋势。主要关注的结局是90天死亡率。次要关注的结局是手术切缘阳性率、切除的淋巴结数量、充分的淋巴结清扫术(>15个淋巴结)、住院时间、再入院率和转为开放手术率。使用Wilcoxon秩和检验和卡方检验对RMIE和tMIE的治疗效果进行适当比较。还进行了多变量回归分析,以减少接受RMIE和tMIE治疗的患者队列差异的影响。
2010年至2016年共进行了6661例微创食管切除术(1543/6661(23.2%)为RMIE,5118/6661(76.8%)为tMIE)。在研究期间,RMIE的比例从2010年的10.4%(64/618)增加到2016年的27.2%(331/1216)(p<0.001)(图1)。RMIE和tMIE的90天死亡率这一主要结局相似(92/1170(7.4%)对305/4148(7.9%),p=0.558)(表2)。RMIE和tMIE的再入院率也相似(6.3对7%,p=0.380)。基于性别、年龄、种族、保险和肿瘤大小,两组患者之间没有差异。接受RMIE和tMIE治疗的患者队列的不同之处在于,RMIE患者的Charlson评分升高率较低,更有可能在学术机构接受治疗,晚期临床T分期和临床淋巴结受累率较高,并且接受了新辅助治疗。在单变量分析中,RMIE的手术切缘阳性率较低(3.9%对6.1%,p=0.001),评估的平均淋巴结数量更多(16.6±9.74对16.1±10.08,p=0.018),转为开放手术率较低(5.4%对11.4%,p<0.001),平均住院时间较短(12.1±10.39对12.8±11.18天,p<0.001)。在多变量分析中,RMIE与较低的转为开放手术风险(OR 0.51,95%CI:0.37-0.70,p<0.001)和较低的手术切缘阳性率(OR 0.62,95%CI:0.41-0.93,p=0.021)相关。此外,在多变量逻辑回归中,RMIE显示出更高的充分淋巴结清扫术(>15个淋巴结)(OR 1.18,95%CI 1.02-1.37,p<0.032)。
在国家癌症数据库中,机器人食管切除术与较低的转为开放手术率和手术切缘阳性状态相关。我们推测RMIE增强的灵活性和可视化有助于术中操作,从而改善这些治疗效果。